In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.33 below Xtant Medical Holdings Inc average.

Within Biotechnology & Pharmaceuticals industry 130 other companies have achieved higher Quick Ratio than Xtant Medical Holdings Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2431, from total ranking in the first quarter 2026 at 3079.

Explain Quick Ratio?
How much Cash & cash equivalents XTNT�s has?
What are XTNT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

XTNT Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	0.36 %	-34.98 %	6.02 %	5.45 %	8.76 %
Y / Y Cash & cash equivalent Change	42.57 %	141.2 %	175.09 %	57.67 %	28.7 %
Quick Ratio MRQ	0.33	0.65	0.58	0.29	0.23
XTNT's Total Ranking	# 2431	# 3079	# 3644	# 3947	# 4203
Seq. Current Liabilities Change	59.61 %	-36.33 %	-16.95 %	18.92 %	3.4 %
Seq. Cash & cash equivalent Change	-18.68 %	-28.83 %	63.97 %	50.22 %	37.58 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 131
Healthcare Sector	# 774
Overall Market	# 2985

Quick Ratio Statistics
High	Average	Low
1.83	0.48	0.02
(Sep 30 2021)		(Sep 30 2017)

Financial Statements
Xtant Medical Holdings Inc 's Current Liabilities	$ 30 Millions	Visit XTNT's Balance sheet
Xtant Medical Holdings Inc 's Cash & cash equivalent	$ 10 Millions	Visit XTNT's Balance sheet
Source of XTNT's Sales		Visit XTNT's Sales by Geography

Cumulative Xtant Medical Holdings Inc 's Quick Ratio

XTNT's Quick Ratio for the trailling 12 Months

XTNT Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-5.39 %	-3.55 %	6.24 %	10.21 %	21.43 %
Y / Y Cash & cash equivalent TTM Growth	99.84 %	100.44 %	73.44 %	28.41 %	1.83 %
Quick Ratio TTM	0.43	0.41	0.32	0.23	0.21
Total Ranking TTM	# 2201	# 2847	# 2420	# 2557	# 2634
Seq. Current Liabilities TTM Growth	0.1 %	-8.16 %	1.37 %	1.53 %	2.04 %
Seq. Cash & cash equivalent TTM Growth	6.34 %	18.03 %	38.01 %	15.37 %	6.65 %

Quick ratio ranking by company, industry and sector >> Back to XTNT Financial Strength Comparisons >> Go to Compare XTNT Quick Ratio to its Competitors

On the trailing twelve months basis XTNT Cash & cash equivalent soared by 42.57 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Xtant Medical Holdings Inc 's Quick Ratio to 0.43, Quick Ratio remained below XTNT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Xtant Medical Holdings Inc . While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents XTNT�s has?
What are XTNT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 143
Healthcare Sector	# 903
Within the Market	# 2431

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.61	0.47	0.05
(Mar 31 2022)		(Sep 30 2017)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Protalix Biotherapeutics inc	0.90	$ 28.140 Millions	$ 31.391 Millions
Vivosim Labs Inc	0.88	$ 1.670 Millions	$ 1.893 Millions
Senti Biosciences Holdings Inc	0.83	$ 13.124 Millions	$ 15.765 Millions
Pelthos Therapeutics Inc	0.78	$ 24.776 Millions	$ 31.959 Millions
Ocugen Inc	0.75	$ 100.051 Millions	$ 133.080 Millions
Sab Biotherapeutics Inc	0.71	$ 8.267 Millions	$ 11.705 Millions
Vaxcyte Inc	0.68	$ 183.190 Millions	$ 271.277 Millions
Halozyme Therapeutics Inc	0.61	$ 231.081 Millions	$ 375.965 Millions
Silexion Therapeutics Corp	0.57	$ 2.258 Millions	$ 3.976 Millions
Atlantic Coastal Acquisition Corp Ii	0.52	$ 4.291 Millions	$ 8.225 Millions
Surrozen Inc	0.50	$ 102.039 Millions	$ 203.292 Millions
Pluri Inc	0.40	$ 13.126 Millions	$ 32.719 Millions
Outlook Therapeutics Inc	0.39	$ 11.242 Millions	$ 28.679 Millions
Neurocrine Biosciences Inc	0.37	$ 390.500 Millions	$ 1,046.100 Millions
Curis Inc	0.37	$ 5.100 Millions	$ 13.675 Millions
Creative Medical Technology Holdings Inc	0.36	$ 0.250 Millions	$ 0.699 Millions
Xtant Medical Holdings Inc	0.33	$ 9.870 Millions	$ 29.963 Millions
Champions Oncology Inc	0.23	$ 4.358 Millions	$ 18.729 Millions
ADAPTIN BIO, INC.	0.22	$ 0.670 Millions	$ 3.036 Millions
Armata Pharmaceuticals Inc	0.10	$ 23.952 Millions	$ 250.199 Millions
Agenus Inc	0.08	$ 18.738 Millions	$ 231.820 Millions

Date modified: 2026-09-26T07:12:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.